A Randomized, Double-Blind, Placebo-Controlled, Parallel Design Clinical Study to Assess the Effect of the Bio-K+ Probiotic Capsules (VL-BK-02) in Adults With Functional Constipation

Status: Recruiting
Location: See all (8) locations...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The present study is a randomized, placebo-controlled, double-blind, parallel-group clinical study designed to assess the effects of IP in individuals with Functional constipation as compared to a placebo. Approximately 205 individuals aged between 18 and 60 years will be screened. Considering a screen failure of 20%, approximately 164 individuals will be randomized in a ratio of 1:1 to receive either the active or placebo. The study will have at least 126 completed participants i.e. 63 partcipants in each study arm after accounting for a dropout/withdrawal rate of 23% at the end of the study. The intervention duration for all the study participants will be 56 days with follow up of upto 84 days. The study flow chart given below indicates the time points at which safety and efficacy assessments will be conducted

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: t
View:

• Individuals agreed to the signed and dated informed consent form.

• Male and female individuals of age between 18 to 60 years (both values included)

• Individuals who meet Rome IV diagnostic criteria for functional constipation is indicated by the following criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis:

• i. Fewer than three SBM per week ii. Any one or more of the below criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis:

⁃ Straining during more than ¼ (25%) of defecations

⁃ Lumpy or hard stools (Bristol Stool Form Scale 1-2) more than ¼ (25%) of defecations

⁃ Sensation of incomplete evacuation more than ¼ (25%) of defecations

⁃ Sensation of anorectal obstruction/ blockage more than ¼ (25%) of defecations

⁃ Manual maneuvers to facilitate more than ¼ (25%) of defecations (e.g., digital evacuation, support of the pelvic floor) iii. Loose stools are rarely present without the use of laxatives iv. Insufficient criteria for irritable bowel syndrome

• Individuals willing to comply with all study procedures and availability for the duration of the study as per the protocol.

• Individuals willing to maintain the same dietary and physical activity practices throughout the study period.

Locations
Other Locations
India
HCG Hospitals
NOT_YET_RECRUITING
Ahmedabad
Jan Kalyan Multispeciality Hospital
ACTIVE_NOT_RECRUITING
Kalyān
Signus Hospital
RECRUITING
Nashik
AK Superspeciality Clinic
RECRUITING
Pune
Care Multispecialty Hospital
RECRUITING
Pune
Lifeline multispecialty Hospital
RECRUITING
Pune
Anand Multispeciality Hospital
RECRUITING
Vadodara
Krishna Hospital
RECRUITING
Varanasi
Contact Information
Primary
Dr. Sanjay Vaze, MBBS
sanjay.v@vediclifesciences.com
8655670964
Backup
Rushikesh Londhe, M.Pharm
rushikesh.l@vediclifesciences.com
8655737996
Time Frame
Start Date: 2025-01-25
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 126
Treatments
Experimental: VL-BK-02 (25 billion CFU/Capsule)
One capsule per day to be consumed orally before breakfast Duration: 84 days (12 weeks)
Placebo_comparator: Placebo (Microcrystalline Cellulose - 375 mg/capsule)
One capsule per day to be consumed orally before breakfast Duration: 84 days (12 weeks)
Related Therapeutic Areas
Sponsors
Leads: Vedic Lifesciences Pvt. Ltd.

This content was sourced from clinicaltrials.gov